Circulating immune complexes in patients with malignant lymphomas and solid tumors
✍ Scribed by Hans Erik Heier; Nicole Carpentier; Ghislaine Lange; Paul Henri Lambert; Tore Godal
- Publisher
- John Wiley and Sons
- Year
- 1977
- Tongue
- French
- Weight
- 664 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Sera from 50 patients with Hodgkin's disease, 78 patients with non‐Hodgkin non‐leukemic malignant lymphomas, and 75 patients with different types of solid malignant tumors were investigated for the presence of immune complexes using the (^125^I) C1q‐binding test. All patients were untreated. An increased serum C1q‐binding activity was found in 22% of the patients with Hodgkin's disease, 35.9% of the non‐Hodgkin lymphoma patients and in 37.3% of the patients with solid tumors. The C1q‐binding material detected in the patients' sera had properties similar to those of immune complexes. On sucrose density gradient it sedimented as a 10‐30 s material. It contained IgG which were dissociated under acid conditions. Passage through anti‐IgG immunoabsorbent removed its C1q‐binding properties. A prevalent association was found between the presence of serum immune complexes and disseminated disease stages in all the patient groups included. A similar association was found between the presence of serum immune complexes and general symptoms among the malignant lymphoma patients. The nature of the antigens involved in the complexes remains unknown.
📜 SIMILAR VOLUMES
## Abstract Sera from 53 patients with Hodgkin's disease (HD) and 56 patients with non‐Hodgkin malignant lymphoma (NH) were investigated, prior to treatment, for the presence of circulating immune complexes (CIC) by the ^125^l‐C1q‐binding radio‐assay. The patients were then followed for 14–31 month
## Abstract Sera from 62 patients with osteogenic sarcoma and 12 with malignant giant‐cell tumour were tested for the presence of immune complexes by the ^125^I‐Clq binding assay. Elevated serum Clq binding activity was found in 67.7% of the osteogenic sarcoma patients and in 75% of the giant‐cell
## Abstract Sera of individuals with Burkitt's lymphoma and nasopharyngeal carcinoma, tested by consumption of hemolytic complement, were found by comparison with healthy individuals to have significantly increased levels of circulating immune complexes. The identity of the immune complexes was est
## Abstract Forty‐one patients with progressive systemic sclerosis were studied for the presence of immune complexes by the fluid‐ and solid‐phase C1q binding, C1 activation, and the fluid‐phase conglutinin assays. Complement activation and autoantibodies were also studied. Immune complexes were de
## Abstract Total hemolytic complement activity (CH 50) and complement component levels were measured in 27 patients with Hodgkin's disease and 31 patients with non‐Hodgkin malignant lymphoma. CH 50 values were higher than normal in almost alt the patients. Increased levels of serum C4, C3 and fact